Market Place
Sourcing Support
Otsuka buys Mindset for CAD 80M to strengthen pipeline in neurological disorders
04 Sep 2023 //
BIOSPECTRUM ASIA
Otsuka Pharmaceutical to Acquire Mindset Pharma
01 Sep 2023 //
BIOSPACE
UK trial to test psilocin-based drug for major depressive disorder
28 Jun 2023 //
EUROPEAN PHARMACEUTICAL REVIEW
Mindset Pharma Files Two Patent Applications for its Non-Hallucinogenic
26 Apr 2023 //
GLOBENEWSWIRE
Mindset Pharma to Participate in the Sequire Cannabis & Psychedelics Conference
03 Apr 2023 //
GLOBENEWSWIRE
Mindset Pharma CEO, James Lanthier, Issues Letter to Shareholders
28 Mar 2023 //
GLOBENEWSWIRE
Mindset Pharma To Defend Against Lawsuit Filed By Reunion Neurosciences
14 Mar 2023 //
GLOBENEWSWIRE
Mindset and PharmAla Complete First Sale of Pharmaceutical Grade Psilocybin
06 Mar 2023 //
GLOBENEWSWIRE
Mindset Pharma Receives Allowance from USPTO for Patent Application
02 Feb 2023 //
GLOBENEWSWIRE
Mindset Receives Allowance for U.S. Patent Application for MSP-1014
20 Jan 2023 //
GLOBENEWSWIRE
Canadian and US developers to trial psychedelic medicines in UK
13 Dec 2022 //
EUROPEANPHARMACEUTICALREVIEW
Mindset Pharma to Participate in Upcoming Conferences in December 2022
06 Dec 2022 //
GLOBENEWSWIRE
Mindset Pharma CEO, James Lanthier Issues Letter to Shareholders
30 Nov 2022 //
GLOBENEWSWIRE
Mindset Pharma and PharmAla Biotech Enter into Exclusive Sales Agreement
16 Nov 2022 //
GLOBENEWSWIRE
Mindset & PharmAla Enter Exclusive Sales Agreement for the Sale &Distribution
16 Nov 2022 //
GLOBENEWSWIRE
Mindset Pharma Presents Poster at Neuroscience 2022 Preclinical Data on MSP-1014
14 Nov 2022 //
GLOBENEWSWIRE
Mindset Announces Poster Presentations at Two Upcoming Scientific Conferences
27 Oct 2022 //
GLOBENEWSWIRE
Mindset Pharma Provides Strategic Intellectual Property License to Cybin
27 Sep 2022 //
GLOBENEWSWIRE
Mindset Pharma Receives Scientific Advice from UK Regulator Ph1 , MSP-1014
14 Sep 2022 //
GLOBENEWSWIRE
Mindset Pharma Files National Patents Protecting Family 1 Application in 16
07 Sep 2022 //
GLOBENEWSWIRE
Mindset Further Expands its IP Portfolio with Three Additional Non-Tryptamine
31 Aug 2022 //
GLOBENEWSWIRE
Mindset Pharma to Participate in the H.C. Wainwright 24th Global Investment
30 Aug 2022 //
GLOBENEWSWIRE
Mindset Pharma Receives Allowance for Patent Covering Psychedelic Medications
06 Jul 2022 //
GLOBENEWSWIRE
Mindset Pharma Announces Development of Novel, Optimized, Intranasal Formulation
29 Jun 2022 //
GLOBENEWSWIRE
Mindset Pharma and CAMH Collaborate to Build Molecular Profile of MSP-1014
22 Jun 2022 //
GLOBENEWSWIRE
Mindset Pharma Receives NoA for Patent Application Covering Psilocin Derivatives
10 Jun 2022 //
GLOBENEWSWIRE
Mindset Pharma to Participate in Upcoming Conferences in June 2022
07 Jun 2022 //
GLOBENEWSWIRE
Mindset Pharma Progresses Plans for Clinical Trials of MSP-1014
12 May 2022 //
GLOBENEWSWIRE
Mindset Pharma to Participate in Upcoming Conferences in May 2022
04 May 2022 //
GLOBENEWSWIRE
Mindset Pharma Strengthens IP Portfolio with New Provisional Patent Application
19 Apr 2022 //
GLOBENEWSWIRE
Mindset Pharma to Participate in Upcoming Conferences in April 2022
05 Apr 2022 //
GLOBENEWSWIRE
Mindset Pharma CEO, James Lanthier, Issues Letter to Shareholders
17 Mar 2022 //
GLOBENEWSWIRE
Mindset Pharma to Participate in Upcoming Investor Conferences in March 2022
03 Mar 2022 //
GLOBENEWSWIRE
Mindset Pharma Enters Manufacturing Agreement with Leading CDMO for MSP-1014
25 Jan 2022 //
GLOBENEWSWIRE
Japan’s Otsuka Pharma invests in development of psychedelic medicines
07 Jan 2022 //
BIOSPECTRUMASIA
MSRD and Mindset Pharma Collaborate to Develop Psychedelic Medicines
05 Jan 2022 //
BUSINESSWIRE
Mindset Pharma Announces Filing of International Patent Application
28 Dec 2021 //
GLOBENEWSWIRE
MindsetAnnounces Poster Presentation of Preclinical Data for Benchmarking
08 Nov 2021 //
GLOBENEWSWIRE
Mindset Pharma Expands Benchmarking Data for First Generation Psychedelics
14 Oct 2021 //
GLOBENEWSWIRE
Mindset Pharma Expands Pipeline: Identifies Additional Next Generation 5-MeO
29 Sep 2021 //
GLOBENEWSWIRE
Mindset Pharma Announces Further Preclinical Results for MSP-4018
20 Sep 2021 //
GLOBENEWSWIRE
Mindset Pharma Further Validates Lead Candidate, MSP-1014
14 Sep 2021 //
GLOBENEWSWIRE
Mindset Pharma`s MSP-1014 to treat neurological and psychiatric disorders
09 Sep 2021 //
GLOBENEWSWIRE
Mindset develops Preclinical Rodent Trained Studies to compare drug effects
07 Sep 2021 //
GLOBENEWSWIRE
Mindset Pharma Announces preclinical results in 5-MeO-DMT Psychedelic Analogs
31 Aug 2021 //
GLOBENEWSWIRE
Mindset Pharma Announces Preclinical Results in next gen Psychedelic Compounds
26 Aug 2021 //
GLOBENEWSWIRE
Mindset Pharma files U.S. Provisional Patent for Psychedelic Drug Candidates
24 Aug 2021 //
GLOBENEWSWIRE
Mindset Pharma Announces Publication of Three PCT Patent Applications
16 Aug 2021 //
GLOBENEWSWIRE
Mindset Pharma Announces Additional Preclinical Results for MSP-1014
07 Jul 2021 //
GLOBENEWSWIRE
Mindset Announce Availability of 1st Preclinical Psychedelic Benchmark Data
14 Jun 2021 //
GLOBENEWSWIRE
Mindset Pharma Announces Promising Test Results of Psilocybin-Inspired Compounds
31 Aug 2020 //
GLOBENEWSWIRE
